摘要
癌胚抗原、神经元特异性烯醇化酶、细胞角蛋白19片段、前胃泌素释放肽和鳞状细胞癌抗原是常用的肺癌标志物。目前,单一的标志物不能用于无症状人群或高危人群的肺癌筛查,但对肺癌的鉴别诊断、疗效评价、复发或转移监测、预后判断具有重要临床价值。对Dickkopf-1、血浆激肽释放酶、MicroRNA等新发现的肺癌标志物还应进行大量的临床应用评价。今后,应积极探究对肺癌特异性和敏感性俱佳的标志物。
Carcinoma embryonic antigen（CEA）,neuron-specific enolase（NSE）,cytokeratin-19 fragments,progastrin-releasing peptide（ProGRP）and squamous cell carcinoma antigen（SCCA）are commonly used tumor markers in lung cancer.Currently,single tumor markers can not be used for screening purposes either in asymptomatic populations or in those at high risk of lung cancer.However,they have important clinical value in the differential diagnosis,therapy efficacy evaluation,monitoring of recurrence or metastasis,and prognosis of lung cancer.A lot of clinical evaluation of Dickkopf-1,plasma kallikrein,MicroRNA and other newly discovered markers of lung cancer should be done.In the future,the lung cancer markers with superb sensitivity and specificity should be actively explored.
出处
《医学综述》
2011年第22期3409-3411,共3页
Medical Recapitulate
关键词
肺癌
肿瘤标志物
临床应用
Lung cancer
Tumor markers
Clinical application
